Camp4 Therapeutics Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 3, 2026, details the completion of the Second Closing of a private placement transaction previously announced in September 2025. Camp4 Therapeutics Corp., an emerging growth company, is advancing its clinical development program, specifically for CMP-002, an investigational product for SYNGAP1-related disorder.
Key Financial Metrics and Transaction Details
- Transaction Type: Second Closing of a Private Placement (Securities Purchase Agreement).
- Gross Proceeds: Approximately $50.1 million (before deducting placement agent fees and expenses).
- Securities Issued:
- 10,756,498 shares of Common Stock at $1.53 per share.
- 21,925,368 pre-funded warrants at $1.5299 per warrant.
- 39,306 shares of Common Stock sold to management and co-founders at $1.65 per share.
- Warrant Terms: Exercise price of $0.0001; exercisable immediately; no expiration until fully exercised; subject to a 19.99% beneficial ownership limitation.
- Liquidity Impact: The filing does not provide specific cash balance, debt, or liquidity ratios. Proceeds are intended to fund operations and clinical trials.
Material Changes and Triggers
The Second Closing was triggered by two key developments in July 2026:
- Regulatory Clearance: Receipt of clearance from Australia's Therapeutic Goods Administration and the local Human Research Ethics Committee to initiate the Phase 1/2 clinical trial of CMP-002 (satisfying the CTA Milestone).
- Price Threshold Waiver: The Company received a waiver satisfying the Second Closing Trigger defined in the Original Agreement.
Outlook, Risks, and Management Commentary
Management has successfully secured funding to continue clinical development. The filing notes that the pre-funded warrants allow investors to convert to common stock at a nominal cost, subject to beneficial ownership limits. No specific forward-looking financial guidance or revenue projections are provided in this filing. The primary risk highlighted is the reliance on the exemption from registration requirements under Section 4(a)(2) of the Securities Act for the unregistered sale of these securities.
Key Facts for Investor Verification
- Verify the exact net proceeds after deducting placement agent fees and transaction expenses, as only gross proceeds ($50.1 million) are stated.
- Confirm the current cash position and runway following the receipt of the Second Closing funds.
- Review the full text of the Amendment (Exhibit 10.1) and the pre-funded warrant terms (Exhibit 4.1) for specific dilution mechanics and beneficial ownership limitations.
- Monitor the progress of the CMP-002 Phase 1/2 clinical trial in Australia as the primary operational milestone.